Literature DB >> 28383445

Anorectal Function and Quality of Life in Patients With Early Stage Rectal Cancer Treated With Chemoradiation and Local Excision.

Patricio B Lynn1, Lindsay A Renfro, Xiomara W Carrero, Qian Shi, Paul L Strombom, Oliver Chow, Julio Garcia-Aguilar.   

Abstract

BACKGROUND: Little is known about anorectal function and quality of life after chemoradiation followed by local excision, which is an alternative to total mesorectal excision for selected patients with early rectal cancer.
OBJECTIVE: The purpose of this study was to prospectively assess anorectal function and health-related quality of life of patients with T2N0 rectal cancer who were treated with an alternative approach.
DESIGN: This was a prospective, phase II trial. SETTINGS: The study was multicentric (American College of Surgeons Oncology Group trial Z6041).
INTERVENTIONS: Patients with stage cT2N0 rectal adenocarcinomas were treated with an oxaliplatin/capecitabine-based chemoradiation regimen followed by local excision. MAIN OUTCOME MEASURES: Anorectal function and quality of life were assessed at enrollment and 1 year postoperatively with the Fecal Incontinence Severity Index, Fecal Incontinence Quality of Life scale, and Functional Assessment of Cancer Therapy-Colorectal Questionnaire. Results were compared, and multivariable analysis was performed to identify predictors of outcome.
RESULTS: Seventy-one patients (98%) were evaluated at enrollment and 66 (92%) at 1 year. Compared with baseline, no significant differences were found on Fecal Incontinence Severity Index scores at 1 year. Fecal Incontinence Quality of Life results were significantly worse in the lifestyle (p < 0.001), coping/behavior (p < 0.001), and embarrassment (p = 0.002) domains. There were no differences in the Functional Assessment of Cancer Therapy overall score, but the physical well-being subscale was significantly worse and emotional well-being was improved after surgery. Treatment with the original chemoradiation regimen predicted worse depression/self-perception and embarrassment scores in the Fecal Incontinence Quality of Life, and male sex was predictive of worse scores in the Functional Assessment of Cancer Therapy overall score and trial outcome index. LIMITATIONS: Small sample size, relatively short follow-up, and absence of information before cancer diagnosis were study limitations.
CONCLUSIONS: Chemoradiation followed by local excision had minimal impact on anorectal function 1 year after surgery. Overall quality of life remained stable, with mixed effects on different subscales. This information should be used to counsel patients about expected outcomes.

Entities:  

Mesh:

Year:  2017        PMID: 28383445      PMCID: PMC5384260          DOI: 10.1097/DCR.0000000000000758

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  24 in total

1.  Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence.

Authors:  T H Rockwood; J M Church; J W Fleshman; R L Kane; C Mavrantonis; A G Thorson; S D Wexner; D Bliss; A C Lowry
Journal:  Dis Colon Rectum       Date:  2000-01       Impact factor: 4.585

2.  Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence: the fecal incontinence severity index.

Authors:  T H Rockwood; J M Church; J W Fleshman; R L Kane; C Mavrantonis; A G Thorson; S D Wexner; D Bliss; A C Lowry
Journal:  Dis Colon Rectum       Date:  1999-12       Impact factor: 4.585

3.  Anorectal and sexual functions after preoperative radiotherapy and full-thickness local excision of rectal cancer.

Authors:  A Gornicki; P Richter; W Polkowski; M Szczepkowski; L Pietrzak; L Kepka; A Rutkowski; K Bujko
Journal:  Eur J Surg Oncol       Date:  2013-12-04       Impact factor: 4.424

Review 4.  Postoperative complications following surgery for rectal cancer.

Authors:  Bogdan C Paun; Scott Cassie; Anthony R MacLean; Elijah Dixon; W Donald Buie
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

5.  Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer.

Authors:  Katrine J Emmertsen; Søren Laurberg
Journal:  Ann Surg       Date:  2012-05       Impact factor: 12.969

6.  Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer.

Authors:  P G Doornebosch; R A E M Tollenaar; M P Gosselink; L P Stassen; C M Dijkhuis; W R Schouten; C J van de Velde; E J R de Graaf
Journal:  Colorectal Dis       Date:  2007-07       Impact factor: 3.788

7.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

8.  A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial.

Authors:  Lisette M Wiltink; Corrie A M Marijnen; Elma Meershoek-Klein Kranenbarg; Cornelis J H van de Velde; Remi A Nout
Journal:  Acta Oncol       Date:  2015-09-25       Impact factor: 4.089

Review 9.  Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis.

Authors:  Martin Loos; Philipp Quentmeier; Tibor Schuster; Ulrich Nitsche; Ralf Gertler; Andreas Keerl; Thomas Kocher; Helmut Friess; Robert Rosenberg
Journal:  Ann Surg Oncol       Date:  2012-12-27       Impact factor: 5.344

10.  Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.

Authors:  Julio Garcia-Aguilar; Lindsay A Renfro; Oliver S Chow; Qian Shi; Xiomara W Carrero; Patricio B Lynn; Charles R Thomas; Emily Chan; Peter A Cataldo; Jorge E Marcet; David S Medich; Craig S Johnson; Samuel C Oommen; Bruce G Wolff; Alessio Pigazzi; Shane M McNevin; Roger K Pons; Ronald Bleday
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

View more
  7 in total

1.  Rationale, development, and design of the Altering Intake, Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors.

Authors:  Virginia Sun; Tracy E Crane; Samantha D Slack; Angela Yung; Sarah Wright; Stephen Sentovich; Kurt Melstrom; Marwan Fakih; Robert S Krouse; Cynthia A Thomson
Journal:  Contemp Clin Trials       Date:  2018-03-19       Impact factor: 2.226

2.  Short- and long-term outcomes in ypT2 rectal cancer patients after neoadjuvant therapy and local excision: a multicentre observational study.

Authors:  Roberto Peltrini; Simone Castiglioni; Nicola Imperatore; Monica Ortenzi; Daniela Rega; Valentina Romeo; Valerio Caracino; Edoardo Liberatore; Massimo Basti; Emanuele Santoro; Umberto Bracale; Paolo Delrio; Felice Mucilli; Mario Guerrieri; Francesco Corcione
Journal:  Tech Coloproctol       Date:  2022-10-14       Impact factor: 3.699

3.  Quality of Life After Radiotherapy for Rectal and Anal Cancer.

Authors:  Shane S Neibart; Sharon L Manne; Salma K Jabbour
Journal:  Curr Colorectal Cancer Rep       Date:  2020-01-16

4.  Clinical Audit of the Radiotherapy Process in Rectal Cancer: Clinical Practice Guidelines and Quality Certification Do Not Avert Variability in Clinical Practice.

Authors:  M G Torras; E Canals; D Jurado-Bruggeman; S Marín-Borras; M Macià; J Jové; A M Boladeras; C Muñoz-Montplet; J Molero; C Picón; M Puigdemont; L Aliste; A Torrents; F Guedea; J M Borras
Journal:  Transl Oncol       Date:  2018-04-26       Impact factor: 4.243

5.  Survival analysis of local excision vs total mesorectal excision for middle and low rectal cancer in pT1/pT2 stage and intermediate pathological risk.

Authors:  I-Li Lai; Jeng-Fu You; Yih-Jong Chern; Wen-Sy Tsai; Jy-Ming Chiang; Pao-Shiu Hsieh; Hsin-Yuan Hung; Chien-Yuh Yeh; Sum-Fu Chiang; Cheng-Chou Lai; Rei-Ping Tang; Jinn-Shiun Chen; Yu-Jen Hsu
Journal:  World J Surg Oncol       Date:  2019-12-09       Impact factor: 2.754

6.  Early and late morbidity of local excision after chemoradiotherapy for rectal cancer.

Authors:  B Teste; P Rouanet; J-J Tuech; A Valverde; B Lelong; M Rivoire; J-L Faucheron; M Jafari; G Portier; B Meunier; I Sielezneff; M Prudhomme; F Marchal; A Dubois; M Capdepont; Q Denost; E Rullier
Journal:  BJS Open       Date:  2021-05-07

7.  Chemoradiation and Local Excision versus Total Mesorectal Excision for T2N0 Rectal Cancer: Comparison of Short- and Long-Term Outcomes from Two Prospective Studies.

Authors:  Patricio B Lynn; Maxime Van der Valk; Yvette H M Claassen; Qian Shi; Maria Widmar; Ester Bastiaannet; Cornelis Van de Velde; Julio Garcia-Aguilar
Journal:  Ann Surg       Date:  2021-07-02       Impact factor: 12.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.